Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, Ayuk FA, Aziz M, Baez J, Choe H, DeFilipp Z, Etra A, Grupp SA, Hexner E, Holler E, Hogan WJ, Kowalyk S, Merli P, Morales G, Nakamura R, Pulsipher MA, Schechter T, Shah J, Spyrou N, Srinagesh HK, Wölfl M, Yanik G, Young R, Kitko CL, Ferrara JLM, Levine JE. Qayed M, et al. Among authors: hogan wj. Transplant Cell Ther. 2024 Mar 27:S2666-6367(24)00294-X. doi: 10.1016/j.jtct.2024.03.022. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38548227 Free article.
Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group.
Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, Amer H, Hogan WJ, Marshall AL, Sethi S, Tran CL, Chen D, Pruthi RK, Ashrani AA, Fervenza FC, Cramer CH 2nd, Rodriguez V, Wolanskyj AP, Thomé SD, Hook CC; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Go RS, et al. Among authors: hogan wj. Mayo Clin Proc. 2016 Sep;91(9):1189-211. doi: 10.1016/j.mayocp.2016.05.015. Epub 2016 Aug 3. Mayo Clin Proc. 2016. PMID: 27497856
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.
DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng GW, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk FA, Choe HK, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E Prof Dr med, Ferrara JLM, Nakamura R, Levine JE, Chen YB. DeFilipp Z, et al. Among authors: hogan wj. Blood Adv. 2024 Apr 19:bloodadvances.2024012561. doi: 10.1182/bloodadvances.2024012561. Online ahead of print. Blood Adv. 2024. PMID: 38640197
Amphiregulin, ST2,and REG3α Biomarker Risk Algorithms as Predictors of Non-Relapse Mortality in Patients with Acute GVHD.
Etra AM, El Jurdi N, Katsivelos N, Kwon D, Gergoudis SC, Morales G, Spyrou N, Kowalyk S, Aguayo-Hiraldo P, Akahoshi Y, Ayuk FA, Baez J, Betts BC, Chanswangphuwana C, Chen YB, Choe HK, DeFilipp Z, Gleich S, Hexner EO, Hogan WJ, Holler E Prof Dr med, Kitko CL, Kraus S, Al Malki MM, MacMillan ML, Pawarode A, Quagliarella F, Qayed M, Reshef R, Schechter-Finkelstein T, Vasova I, Weisdorf DJ, Wölfl M, Young R, Nakamura R, Ferrara JLM, Levine JE, Holtan SG. Etra AM, et al. Among authors: hogan wj. Blood Adv. 2024 Apr 19:bloodadvances.2023011049. doi: 10.1182/bloodadvances.2023011049. Online ahead of print. Blood Adv. 2024. PMID: 38640195
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Steinauer N, et al. Among authors: hogan wj. Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.284962. Online ahead of print. Haematologica. 2024. PMID: 38546692 Free article.
Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases.
Farrukh F, Abdelmagid M, Mangaonkar A, Patnaik M, Al-Kali A, Elliott MA, Begna KH, Hook CC, Hogan WJ, Pardanani A, Litzow MR, Ketterling RP, Gangat N, Arber DA, Orazi A, He R, Reichard K, Tefferi A. Farrukh F, et al. Among authors: hogan wj. Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284719. Online ahead of print. Haematologica. 2024. PMID: 38450522 Free article.
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.
Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Kasikis S, Katsivelos N, Kowalyk S, Morales G, Young R, DeFilipp Z, Ferrara JLM, Levine JE, Nakamura R. Akahoshi Y, et al. Among authors: hogan wj. Blood Adv. 2024 Apr 23;8(8):2047-2057. doi: 10.1182/bloodadvances.2023012091. Blood Adv. 2024. PMID: 38324721 Free PMC article.
A Day 14 Endpoint for Acute GVHD Clinical Trials.
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki MM, Ayuk F, Bader P, Baez J, Capellini A, Choe H, DeFilipp Z, Eder M, Eng G, Etra A, Gleich S, Grupp SA, Hexner E, Hoepting M, Hogan WJ, Kasikis S, Katsivelos N, Khan A, Kitko CL, Kraus S, Kwon D, Merli P, Portelli J, Qayed M, Reshef R, Schechter T, Vasova I, Wölfl M, Wudhikarn K, Young R, Holler E, Chen YB, Nakamura R, Levine JE, Ferrara JLM. Spyrou N, et al. Among authors: hogan wj. Transplant Cell Ther. 2024 Apr;30(4):421-432. doi: 10.1016/j.jtct.2024.01.079. Epub 2024 Feb 4. Transplant Cell Ther. 2024. PMID: 38320730 Free article.
554 results